The Latest Cardiac and Vascular News
– Presentation of cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial receives AHA’s “Cardiopulmonary Best Abstract” Award – – AHA sessions to include data from the ongoing SPECTRA Phase 2 trial – – Acceleron to host investor and analyst conference call and webcast with guest PAH […]
The multi-year strategic partnership will enable GenesisCare to offer patients greater access to leading technology, with a plan to explore further collaborations to improve cancer diagnosis, treatment and cardiovascular care The agreement is valued at more than USD 130 million over the next five years, including imaging technologies, digital solutions, […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced two presentations highlighting gene editing as a potentially transformative therapeutic approach at the American Heart Association (AHA) Scientific Sessions 2020, taking place virtually November 13-17, 2020. Verve is developing one-time gene editing medicines […]
Third quarter 2020 revenue returns to pre-COVID-19 levels Management to host investor conference call today, November 9, 2020 at 8:30 a.m. ET TEL AVIV, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR)(“Inspire” or the “Company”), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention […]
ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020. “Stereotaxis is pleased to report revenue growth with the successful installation of the first Genesis RMN® and […]
Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials SANTA CLARA, Calif., Nov. 07, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, reported today that investigators […]
Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high […]
SAN JOSE, Calif., Nov. 7, 2020 /PRNewswire/ — VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the final round of anticipated late-breaking clinical trial results presented at the VIVA20 virtual meeting. Below are highlights of today’s late-breaking clinical trial presentations: […]
Introducing a new portfolio of heart valve products aiming to restore health and extend life HONG KONG, Nov. 9, 2020 /PRNewswire/ — OrbusNeich and P+F today announced they have entered into an agreement for the exclusive distribution and manufacturing of a range of innovative minimally invasive heart valve products in the Asia Pacific region, including China, Japan, Taiwan, South […]
Matrix Plus promotes functional and structural maturation of hiPSC-CMs in seven days compared to partial maturation obtained within 30 to 100 days with current approaches SAN ANTONIO and ANN ARBOR, Mich., Nov. 9, 2020 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix […]
